Acute Kidney Injury (AKI) epidemiology report gives a thorough understanding of the Acute Kidney Injury (AKI) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

Acute Kidney Injury (AKI) Epidemiology Forecast

<h2 class="MsoNormal">Key Highlights</h2>
<ul>
<li class="MsoNormal">The incidence of AKI is on the rise, particularly in individuals with acute illnesses and potentially those undergoing significant surgical procedures.</li>
<li class="MsoNormal">Total mortality-adjusted incident cases of AKI in hospitalized patients in the 7MM accounted for approximately 14.6 million in 2022. The rate decreased during the COVID-19 pandemic.</li>
<li class="MsoNormal">The stage-specific cases of AKI include Stage I, Stage II, and, Stage III. Out of which maximum cases were reported in stage I AKI followed by stage II and Stage III.</li>
</ul>
&nbsp;
DelveInsight's "Acute Kidney Injury&ndash;Epidemiology&ndash;2034&rdquo; report delivers an in-depth understanding of the AKI, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
<h2 class="MsoNormal">Geography Covered</h2>
<ul>
<li class="MsoNormal">The United States</li>
<li class="MsoNormal">EU4 (Germany, France, Italy, and Spain) and the United Kingdom</li>
<li class="MsoNormal">Japan</li>
</ul>
Study Period: 2021-2034
<h2 class="MsoNormal">AKI Disease Understanding</h2>
Acute Kidney Injury Overview
AKI is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over hours to weeks. Signs and symptoms of AKI include nausea, vomiting, weakness, dizziness, and, pain in the lower back. Some patients are asymptomatic (no noticeable symptoms) and others may have generalized non-specific (not specific to kidneys) symptoms.
&nbsp;
Acute Kidney Injury Diagnosis
The history and physical examination are important in determining the etiology of AKI. The history can identify nephrotoxic medications or a systemic illness contributing to impaired renal function. The physical examination should focus on evaluating intravascular volume status. Skin rashes may indicate an underlying condition (e.g., systemic lupus erythematosus, atheroembolism/vasculitis) or exposure (e.g., drug rash suggesting acute interstitial necrosis) leading to acute kidney injury. The diagnosis of AKI is traditionally based on a rise in serum creatinine and/or a fall in urine output. The laboratory assessment includes the measurement of serum creatinine level, urinalysis, renal biopsy, urine electrolytes, and others.
Further details related to diagnosis are provided in the report&hellip;
<h2 class="MsoNormal">AKI Epidemiology</h2>
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of AKI in Hospitalized Patients, Mortality Adjusted Incident Population of AKI in Hospitalized Patients, Stage-specific Incident Population of AKI, and, Age-specific Incident Population of AKI in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2021 to 2034.
<ul>
<li class="MsoNormal">The total Mortality-adjusted Incident Cases of AKI in the 7MM comprised 14.6 million cases in 2022 and are projected to increase during the forecast period.</li>
<li class="MsoNormal">The total Mortality-adjusted Incident Cases of AKI in the United States were approximately 5.7 million in 2022.&nbsp;</li>
<li class="MsoNormal">The US contributed to the largest incident population of AKI, accounting for ~ 39% in the 7MM in 2022.</li>
<li class="MsoNormal">Among EU4 and the UK, Germany accounted for the highest number of AKI cases, followed by France, whereas Spain accounted for the lowest cases in 2022.</li>
</ul>
<h2 class="MsoNormal">KOL- Views</h2>
To keep up with current epidemiology trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MD, Professor and Vice Chair Department of Critical Care Medicine and Director, Center for Critical Care Nephrology, PhD, and others.
&nbsp;
Delveinsight&rsquo;s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Center for Kidney Diseases, Department of Rheumatology, Department of Nephrology, etc., were contacted. Their opinion helps understand and validate AKI epidemiology trends.
<h2 class="MsoNormal">Scope of the Report</h2>
<ul>
<li class="MsoNormal">The report covers a segment of key events, an executive summary, descriptive overview of AKI, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.</li>
<li class="MsoNormal">Comprehensive insight into the epidemiology segments and forecasts of disease progression has been provided.</li>
<li class="MsoNormal">The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journeys in the 7MM.</li>
</ul>
<h2 class="MsoNormal">AKI Report Insights</h2>
<ul>
<li class="MsoNormal">AKI Report Insights</li>
<li class="MsoNormal">Patient Population</li>
<li class="MsoNormal">Country-wise Epidemiology Distribution</li>
</ul>
<h2 class="MsoNormal">AKI Report Key Strengths</h2>
<ul>
<li class="MsoNormal">Eleven Years Forecast</li>
<li class="MsoNormal">7MM Coverage</li>
<li class="MsoNormal">AKI Epidemiology Segmentation</li>
</ul>
&nbsp;
<h2 class="MsoNormal">AKI Report Assessment</h2>
<ul>
<li class="MsoNormal">Unmet Needs</li>
<li class="MsoNormal">Current Diagnostic Practices</li>
</ul>
<h2 class="MsoNormal">FAQs</h2>
<ul>
<li class="MsoNormal">What are the disease risks, burdens, and unmet needs of AKI? What will be the growth opportunities across the 7MM concerning the patient population with AKI?</li>
<li class="MsoNormal">What is the historical and forecasted AKI patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?</li>
</ul>
<h2 class="MsoNormal">Reasons to Buy</h2>
<ul>
<li class="MsoNormal">Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.</li>
<li class="MsoNormal">To understand the incident cases of AKI in varying geographies over the coming years.</li>
<li class="MsoNormal">To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis.</li>
<li class="MsoNormal">Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.</li>
</ul>

1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY
4. EPIDEMIOLOGY METHODOLOGY
5. ACUTE KIDNEY INJURY (AKI) MARKET OVERVIEW AT A GLANCE IN THE 7MM
5.1. PATIENT SHARE (%) DISTRIBUTION IN 2021
5.2. PATIENT SHARE (%) DISTRIBUTION IN 2034
6. DISEASE BACKGROUND AND OVERVIEW
6.1. INTRODUCTION
6.2. SYMPTOMS
6.3. TYPES OF ACUTE KIDNEY INJURY
6.4. STAGES CLASSIFICATION
6.5. RISK FACTORS
6.6. ETIOLOGY
6.7. PATHOPHYSIOLOGY
6.8. BIOMARKERS
6.9. DIAGNOSIS
6.9.1. RIFLE Criteria
6.9.2. AKIN Criteria
6.9.3. KDIGO criteria
7. TREATMENT AND PREVENTION
7.1. ACUTE RENAL FAILURE OR ACUTE KIDNEY INJURY: UNITED STATES BASED TREATMENT GUIDELINES
7.2. EUROPEAN RENAL BEST PRACTICE (ERBP) POSITION STATEMENT ON THE KIDNEY DISEASE IMPROVING GLOBAL OUTCOMES (KDIGO) CLINICAL PRACTICE GUIDELINES ON ACUTE KIDNEY INJURY
7.3. THE JAPANESE CLINICAL PRACTICE GUIDELINE FOR ACUTE KIDNEY INJURY (2016)
7.4. NICE GUIDELINES ON AKI: PREVENTION, DETECTION, AND MANAGEMENT (2021)
7.4.1. Assessing Risk of AKI
7.4.2. Preventing AKI
7.4.3. Detecting AKI
7.4.4. Identifying the Cause of AKI
7.4.5. Managing AKI
7.4.6. Information and Support for Patients and Carers
8. EPIDEMIOLOGY AND PATIENT POPULATION
8.1. KEY FINDINGS
8.2. ASSUMPTIONS AND RATIONALE
8.2.1. United States
8.2.2. EU4 and the UK
8.2.3. Japan
8.3. TOTAL INCIDENCE OF ACUTE KIDNEY INJURY (AKI) IN HOSPITALIZED PATIENTS IN THE 7MM
8.4. TOTAL MORTALITY ADJUSTED INCIDENT POPULATION OF AKI IN HOSPITALIZED PATIENTS IN THE 7MM
8.5. THE UNITED STATES
8.5.1. Total Incident Population of AKI in Hospitalized Patients in the US
8.5.2. Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the US
8.5.3. Stage-specific Incident Population of AKI in the US
8.5.4. Age-specific Incident Population of AKI in the US
8.6. EU4 and the UK
8.6.1. Total Incident Population of AKI in Hospitalized Patients in EU4 and the UK
8.6.2. Mortality Adjusted Incident Population of AKI in Hospitalized Patients in EU4 and the UK
8.6.3. Stage-specific Incident Population of AKI in EU4 and the UK
8.6.4. Age-specific Incident Population of AKI in EU4 and the UK
8.7. JAPAN
8.7.1. Total Incident Population of AKI in Hospitalized Patients in Japan
8.7.2. Mortality Adjusted Incidence of AKI in Hospitalized Patients in Japan
8.7.3. Stage-specific Incident Population of AKI in Japan
8.7.4. Age-specific Incidence of AKI in Japan
9. PATIENT JOURNEY
10. APPENDIX
10.1. BIBLIOGRAPHY
10.2. REPORT METHODOLOGY
11. DELVEINSIGHT CAPABILITIES
12. DISCLAIMER
 
13. ABOUT DELVEINSIGHT

DelveInsight's "Acute Kidney Injury (AKI) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Acute Kidney Injury (AKI) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute Kidney Injury (AKI) Epidemiology 

Acute Kidney Injury (AKI) - Epidemiology Forecast - 2034

DelveInsight's Acute Kidney Injury (AKI) - Epidemiology Forecast 2034 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of AKI...